
Cognition Therapeutics Inc
NASDAQ:CGTX

Intrinsic Value
The intrinsic value of one
CGTX
stock under the Base Case scenario is
0.404
USD.
Compared to the current market price of 0.239 USD,
Cognition Therapeutics Inc
is
Undervalued by 41%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Cognition Therapeutics Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Cognition Therapeutics Inc
Balance Sheet Decomposition
Cognition Therapeutics Inc
Current Assets | 22.9m |
Cash & Short-Term Investments | 16.4m |
Receivables | 4.8m |
Other Current Assets | 1.7m |
Non-Current Assets | 634k |
PP&E | 634k |
Free Cash Flow Analysis
Cognition Therapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Cognition Therapeutics Inc
Revenue
|
0
USD
|
Operating Expenses
|
-53.6m
USD
|
Operating Income
|
-53.6m
USD
|
Other Expenses
|
20.3m
USD
|
Net Income
|
-33.3m
USD
|
CGTX Profitability Score
Profitability Due Diligence
Cognition Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Score
Cognition Therapeutics Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
CGTX Solvency Score
Solvency Due Diligence
Cognition Therapeutics Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.

Score
Cognition Therapeutics Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CGTX Price Targets Summary
Cognition Therapeutics Inc
Dividends
Current shareholder yield for CGTX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
CGTX
stock under the Base Case scenario is
0.404
USD.
Compared to the current market price of 0.239 USD,
Cognition Therapeutics Inc
is
Undervalued by 41%.